肠道菌群与HER2阳性乳腺癌的相关性研究进展
Research Advances in the Association between Gut Microbiota and HER2-Positive Breast Cancer
DOI: 10.12677/acm.2025.1561834, PDF,   
作者: 龙腾江, 张 帆*：重庆医科大学，重庆；重庆市人民医院乳腺甲状腺外科，重庆
关键词: 肠道菌群；HER2阳性乳腺癌；Gut Microbiota； HER2-Positive Breast Cancer
摘要: 人表皮生长因子受体2 (HER2)阳性乳腺癌作为侵袭性强、预后较差的乳腺癌亚型，其治疗耐药性与复发转移问题亟待突破。近年来，肠道菌群与肿瘤微环境的交互作用成为研究热点，其通过调控药物代谢、重塑免疫应答及调节炎症微环境等机制，显著影响HER2阳性乳腺癌的发生发展与治疗反应。本文将从肠道菌群与HER2阳性乳腺癌的关系、肠道菌群与HER2阳性乳腺癌的化学治疗、肠道菌群与抗HER2靶向治疗、肠道菌群在HER2阳性乳腺癌中的潜在应用等方面进行文献综述。
Abstract: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer, an aggressive subtype with poor prognosis, presents a critical challenge due to therapeutic resistance, recurrence, and metastasis. In recent years, the interaction between the gut microbiota and the tumor microenvironment has emerged as a significant area of research. The gut microbiota significantly influences the development, progression, and treatment response of HER2-positive breast cancer through mechanisms such as modulating drug metabolism, reshaping immune responses, and regulating the inflammatory microenvironment. This review aims to provide an overview of the relationship between the gut microbiota and HER2-positive breast cancer, its impact on chemotherapy, its role in anti-HER2 targeted therapy, and the potential applications of gut microbiota in HER2-positive breast cancer.
文章引用：龙腾江, 张帆. 肠道菌群与HER2阳性乳腺癌的相关性研究进展[J]. 临床医学进展, 2025, 15(6): 1135-1140. https://doi.org/10.12677/acm.2025.1561834

参考文献

[1] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. [Google Scholar] [CrossRef] [PubMed]
[2] Schlam, I. and Swain, S.M. (2021) HER2-Positive Breast Cancer and Tyrosine Kinase Inhibitors: The Time Is Now. npj Breast Cancer, 7, Article No. 56. [Google Scholar] [CrossRef] [PubMed]
[3] Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001) Use of Chemotherapy Plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine, 344, 783-792. [Google Scholar] [CrossRef] [PubMed]
[4] Routy, B., Le Chatelier, E., Derosa, L., et al. (2018) Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy against Epithelial Tumors. Science, 359, 91-97.
[5] Gopalakrishnan, V., Spencer, C.N., Nezi, L., et al. (2018) Gut Microbiome Modulates Response to Anti-PD-1 Immunotherapy in Melanoma Patients. Science, 359, 97-103.
[6] Goedert, J.J., Jones, G., Hua, X., Xu, X., Yu, G., Flores, R., et al. (2015) Investigation of the Association between the Fecal Microbiota and Breast Cancer in Postmenopausal Women: A Population-Based Case-Control Pilot Study. JNCI: Journal of the National Cancer Institute, 107, djv147. [Google Scholar] [CrossRef] [PubMed]
[7] Bobin-Dubigeon, C., Luu, H.T., Leuillet, S., Lavergne, S.N., Carton, T., Le Vacon, F., et al. (2021) Faecal Microbiota Composition Varies between Patients with Breast Cancer and Healthy Women: A Comparative Case-Control Study. Nutrients, 13, Article 2705. [Google Scholar] [CrossRef] [PubMed]
[8] Aarnoutse, R., Hillege, L.E., Ziemons, J., De Vos-Geelen, J., de Boer, M., Aerts, E.M.E.R., et al. (2021) Intestinal Microbiota in Postmenopausal Breast Cancer Patients and Controls. Cancers, 13, Article 6200. [Google Scholar] [CrossRef] [PubMed]
[9] Guan, X., Ma, F., Sun, X., Li, C., Li, L., Liang, F., et al. (2020) Gut Microbiota Profiling in Patients with HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those under Conventional Dosage. Frontiers in Oncology, 10, Article 902. [Google Scholar] [CrossRef] [PubMed]
[10] Fernández, M.F., Reina-Pérez, I., Astorga, J.M., Rodríguez-Carrillo, A., Plaza-Díaz, J. and Fontana, L. (2018) Breast Cancer and Its Relationship with the Microbiota. International Journal of Environmental Research and Public Health, 15, Article 1747. [Google Scholar] [CrossRef] [PubMed]
[11] Zhu, J., Liao, M., Yao, Z., Liang, W., Li, Q., Liu, J., et al. (2018) Breast Cancer in Postmenopausal Women Is Associated with an Altered Gut Metagenome. Microbiome, 6, Article No. 136. [Google Scholar] [CrossRef] [PubMed]
[12] Wu, A.H., Tseng, C., Vigen, C., Yu, Y., Cozen, W., Garcia, A.A., et al. (2020) Gut Microbiome Associations with Breast Cancer Risk Factors and Tumor Characteristics: A Pilot Study. Breast Cancer Research and Treatment, 182, 451-463. [Google Scholar] [CrossRef] [PubMed]
[13] Yang, P., Wang, Z., Peng, Q., Lian, W. and Chen, D. (2021) Comparison of the Gut Microbiota in Patients with Benign and Malignant Breast Tumors: A Pilot Study. Evolutionary Bioinformatics, 17, 1-10. [Google Scholar] [CrossRef] [PubMed]
[14] Mccarron, A.J., Armstrong, C., Glynn, G., Millar, B.C., Rooney, P.J., Goldsmith, C.E., et al. (2012) Antibacterial Effects on Acinetobacter Species of Commonly Employed Antineoplastic Agents Used in the Treatment of Haematological Malignancies: An in Vitro Laboratory Evaluation. British Journal of Biomedical Science, 69, 14-17. [Google Scholar] [CrossRef] [PubMed]
[15] Lehouritis, P., Cummins, J., Stanton, M., Murphy, C.T., McCarthy, F.O., Reid, G., et al. (2015) Local Bacteria Affect the Efficacy of Chemotherapeutic Drugs. Scientific Reports, 5, Article No. 14554. [Google Scholar] [CrossRef] [PubMed]
[16] Yang, J., Liu, K., Qu, J. and Wang, X. (2013) The Changes Induced by Cyclophosphamide in Intestinal Barrier and Microflora in Mice. European Journal of Pharmacology, 714, 120-124. [Google Scholar] [CrossRef] [PubMed]
[17] Fijlstra, M., Ferdous, M., Koning, A.M., Rings, E.H.H.M., Harmsen, H.J.M. and Tissing, W.J.E. (2014) Substantial Decreases in the Number and Diversity of Microbiota during Chemotherapy-Induced Gastrointestinal Mucositis in a Rat Model. Supportive Care in Cancer, 23, 1513-1522. [Google Scholar] [CrossRef] [PubMed]
[18] Chiba, A., Bawaneh, A., Velazquez, C., Clear, K.Y.J., Wilson, A.S., Howard-McNatt, M., et al. (2020) Neoadjuvant Chemotherapy Shifts Breast Tumor Microbiota Populations to Regulate Drug Responsiveness and the Development of Metastasis. Molecular Cancer Research, 18, 130-139. [Google Scholar] [CrossRef] [PubMed]
[19] Hussein, M.H., Schneider, E.K., Elliott, A.G., Han, M., Reyes-Ortega, F., Morris, F., et al. (2017) From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative “Superbugs” Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators. Microbial Drug Resistance, 23, 640-650. [Google Scholar] [CrossRef] [PubMed]
[20] Scott, S.A., Spencer, C.T., O’Reilly, M.C., Brown, K.A., Lavieri, R.R., Cho, C., et al. (2014) Discovery of Desketoraloxifene Analogues as Inhibitors of Mammalian, Pseudomonas aeruginosa, and NAPE Phospholipase D Enzymes. ACS Chemical Biology, 10, 421-432. [Google Scholar] [CrossRef] [PubMed]
[21] Luxo, C., Jurado, A.S., Custódio, J.B.A. and Madeira, V.M.C. (2001) Toxic Effects of Tamoxifen on the Growth and Respiratory Activity of Bacillus stearothermophilus. Toxicology in Vitro, 15, 303-305. [Google Scholar] [CrossRef] [PubMed]
[22] An, L., Wuri, J., Zheng, Z., Li, W. and Yan, T. (2021) Microbiota Modulate Doxorubicin induced Cardiotoxicity. European Journal of Pharmaceutical Sciences, 166, Article 105977. [Google Scholar] [CrossRef] [PubMed]
[23] Sheahan, B.J., Theriot, C.M., Cortes, J.E. and Dekaney, C.M. (2022) Prolonged Oral Antimicrobial Administration Prevents Doxorubicin-Induced Loss of Active Intestinal Stem Cells. Gut Microbes, 14, Article 2018898. [Google Scholar] [CrossRef] [PubMed]
[24] Ramakrishna, C., Corleto, J., Ruegger, P.M., Logan, G.D., Peacock, B.B., Mendonca, S., et al. (2019) Dominant Role of the Gut Microbiota in Chemotherapy Induced Neuropathic Pain. Scientific Reports, 9, Article No. 20324. [Google Scholar] [CrossRef] [PubMed]
[25] Frank, M., Hennenberg, E.M., Eyking, A., Rünzi, M., Gerken, G., Scott, P., et al. (2015) TLR Signaling Modulates Side Effects of Anticancer Therapy in the Small Intestine. The Journal of Immunology, 194, 1983-1995. [Google Scholar] [CrossRef] [PubMed]
[26] Motoori, M., Yano, M., Miyata, H., Sugimura, K., Saito, T., Omori, T., et al. (2017) Randomized Study of the Effect of Synbiotics during Neoadjuvant Chemotherapy on Adverse Events in Esophageal Cancer Patients. Clinical Nutrition, 36, 93-99. [Google Scholar] [CrossRef] [PubMed]
[27] Cuozzo, M., Castelli, V., Avagliano, C., Cimini, A., d’Angelo, M., Cristiano, C., et al. (2021) Effects of Chronic Oral Probiotic Treatment in Paclitaxel-Induced Neuropathic Pain. Biomedicines, 9, Article 346. [Google Scholar] [CrossRef] [PubMed]
[28] Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., et al. (2013) The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide. Science, 342, 971-976. [Google Scholar] [CrossRef] [PubMed]
[29] Daillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., et al. (2016) Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity, 45, 931-943. [Google Scholar] [CrossRef] [PubMed]
[30] Fluckiger, A., Daillère, R., Sassi, M., et al. (2020) Cross-Reactivity between Tumor MHC Class I-Restricted Antigens and an Entero-Coccal Bacteriophage. Science, 369, 936-942.
[31] Bianchini, G. and Gianni, L. (2014) The Immune System and Response to HER2-Targeted Treatment in Breast Cancer. The Lancet Oncology, 15, e58-e68. [Google Scholar] [CrossRef] [PubMed]
[32] Di Modica, M., Gargari, G., Regondi, V., Bonizzi, A., Arioli, S., Belmonte, B., et al. (2021) Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer. Cancer Research, 81, 2195-2206. [Google Scholar] [CrossRef] [PubMed]
[33] Wang, Y., Wiesnoski, D.H., Helmink, B.A., Gopalakrishnan, V., Choi, K., DuPont, H.L., et al. (2019) Author Correction: Fecal Microbiota Transplantation for Refractory Immune Checkpoint Inhibitor-Associated Colitis. Nature Medicine, 25, Article 188. [Google Scholar] [CrossRef] [PubMed]
[34] Baruch, E.N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., et al. (2021) Fecal Microbiota Transplant Promotes Response in Immunotherapy-Refractory Melanoma Patients. Science, 371, 602-609. [Google Scholar] [CrossRef] [PubMed]
[35] Davar, D., Dzutsev, A.K., McCulloch, J.A., Rodrigues, R.R., Chauvin, J., Morrison, R.M., et al. (2021) Fecal Microbiota Transplant Overcomes Resistance to Anti-PD-1 Therapy in Melanoma Patients. Science, 371, 595-602. [Google Scholar] [CrossRef] [PubMed]
[36] Tanoue, T., Morita, S., Plichta, D.R., Skelly, A.N., Suda, W., Sugiura, Y., et al. (2019) A Defined Commensal Consortium Elicits CD8 T Cells and Anti-Cancer Immunity. Nature, 565, 600-605. [Google Scholar] [CrossRef] [PubMed]
[37] Sivan, A., Corrales, L., Hubert, N., Williams, J.B., Aquino-Michaels, K., Earley, Z.M., et al. (2015) Commensal Bifidobacterium Promotes Antitumor Immunity and Facilitates Anti-PD-L1 Efficacy. Science, 350, 1084-1089. [Google Scholar] [CrossRef] [PubMed]
[38] Wastyk, H.C., Fragiadakis, G.K., Perelman, D., Dahan, D., Merrill, B.D., Yu, F.B., et al. (2021) Gut-Microbiota-Targeted Diets Modulate Human Immune Status. Cell, 184, 4137-4153.E14. [Google Scholar] [CrossRef] [PubMed]
[39] Uribe-Herranz, M., Bittinger, K., Rafail, S., Guedan, S., Pierini, S., Tanes, C., et al. (2018) Gut Microbiota Modulates Adoptive Cell Therapy via CD8α Dendritic Cells and IL-12. JCI Insight, 3, e94952. [Google Scholar] [CrossRef] [PubMed]

为你推荐